Patents by Inventor Ori Kalid

Ori Kalid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nuclear transport modulators and uses thereof
    Patent number: 11945794
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: April 2, 2024
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Antiviral agents for drug-resistant influenza A
    Patent number: 11365174
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: June 21, 2022
    Assignees: Thomas Jefferson University, Ramot At Tel-Aviv University LTD.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20220177445
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: August 23, 2021
    Publication date: June 9, 2022
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF
    Publication number: 20210403459
    Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Application
    Filed: March 18, 2021
    Publication date: December 30, 2021
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Nuclear transport modulators and uses thereof
    Patent number: 11124493
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: September 21, 2021
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
    Patent number: 11008309
    Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: May 18, 2021
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER
    Publication number: 20200399262
    Abstract: The present invention relates to compounds for inhibiting protein degradation and/or the ubiquitin-proteasome system and/or for modulating autophagy, pharmaceutical composition and methods of use thereof in the treatment of cancer.
    Type: Application
    Filed: March 7, 2019
    Publication date: December 24, 2020
    Applicant: PI Therapeutics Ltd
    Inventors: Ori KALID, Irina GOTLIV, Einat LEVY-APTER, Danit FINKELSHTEIN BEKER, Parkash JAGTAP
  • ANTIVIRAL AGENTS FOR DRUG-RESISTANT INFLUENZA A
    Publication number: 20200392076
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through adminstration of the same.
    Type: Application
    Filed: April 27, 2020
    Publication date: December 17, 2020
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlor, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20200199099
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: July 23, 2019
    Publication date: June 25, 2020
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Antiviral agents for amantadine-resistant influenza A
    Patent number: 10676428
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 9, 2020
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF
    Publication number: 20200102292
    Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Application
    Filed: July 10, 2019
    Publication date: April 2, 2020
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Nuclear transport modulators and uses thereof
    Patent number: 10407405
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: September 10, 2019
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
    Patent number: 10399963
    Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: September 3, 2019
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • ANTIVIRAL AGENTS FOR AMANTADINE-RESISTANT INFLUENZA A
    Publication number: 20180370910
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Application
    Filed: December 19, 2016
    Publication date: December 27, 2018
    Applicants: Thomas Jefferson University, Ramot at Tel-Aviv University Ltd.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF
    Publication number: 20180319779
    Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Application
    Filed: December 4, 2017
    Publication date: November 8, 2018
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Multicyclic compounds and methods of using same
    Patent number: 9994558
    Abstract: The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: June 12, 2018
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20180155317
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: July 17, 2017
    Publication date: June 7, 2018
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Methods, compounds, and compositions for inhibition of ROS
    Patent number: 9963452
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: AUGUSTA PHARMACEUTICALS INC.
    Inventors: Dorre A. Grueneberg, Ori Kalid, Jun Xian, Sharanappa B. Rajur, Hwa-Ok Kim, Venugopal Rao Neelagiri, Paresh Salgaonkar, Divakaramenon Sethumadhavan, Chaeho Moon, Madhavi Neelagiri
  • Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
    Patent number: 9938258
    Abstract: The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: April 10, 2018
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shechter, Sharon Shacham, Dilara McCauley, William Senapedis, Gali Golan, Ori Kalid
  • Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
    Patent number: 9856241
    Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: January 2, 2018
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter